RS49945B - Postupak za sintetizovanje inhibitora cox-2 - Google Patents

Postupak za sintetizovanje inhibitora cox-2

Info

Publication number
RS49945B
RS49945B YUP-641/00A YU64100A RS49945B RS 49945 B RS49945 B RS 49945B YU 64100 A YU64100 A YU 64100A RS 49945 B RS49945 B RS 49945B
Authority
RS
Serbia
Prior art keywords
6alkyl
aryl
formula
mnhc1
aralkyl
Prior art date
Application number
YUP-641/00A
Other languages
English (en)
Inventor
Kai Rossen
Robert D. Larsen
Edward G. Corley
Ian W. Davies
Philip Pye
Original Assignee
Merck & Co.Inc.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co.Inc., filed Critical Merck & Co.Inc.,
Publication of YU64100A publication Critical patent/YU64100A/sh
Publication of RS49945B publication Critical patent/RS49945B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
    • C07C251/30—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having nitrogen atoms of imino groups quaternised

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Postupak za sintezu jedinjenja formule I: u kome: su 0-2 R grupe prisutne; svako R, R' i R" nezavisno predstavljaju C1-10alkil, C6-10aril, aralkil, halo, -S(O)mH, S(O)mC1-6alkil, -S(O)m aril, nitro, amino, C1-6alkilamino, di-C1-6alkilamino, -S(O)mNH2, S(O)mNHC1-6alkil, -S(O)mNHC(O)CF3 i cijano, alkil i aril grupe, i alkilni i arilni delovi aralkila, -S(O)mC1-6alkil, -S(O)maril, C1-6alkilamino, di-C1-6alkilamino i -S(O)mNHC1-6alkil se opciono zamenjuju sa 1-3 grupe izabrane od C1-4alkila, arila, halo, hidroksila, -S(O)mH, -S(O)mC1-6alkil, -CN, C1-6alkoksi, amino, C1-6alkilamino, di-C1-6alkilamino, -S(O)mNH2, -S(O)mNHC1-6alkil, -S(O)mNHC(O)CF3 i ariloksi; Y je C ili N; i m je 0, 1 ili 2, naznačen time što obuhvata reakciju jedinjenja formule II: gde R2 do R5, svaki nezavisno predstavljaju C1-6alkil, aril ili aralkil, a X- predstavlja podesan anjon, sa jedinjenjem formule III: u kome su R, R' i Y onakvi, kao što su prethodno određeni, u prisustvu baze da bi se proizvelo jedinjenje formule I. Prijava sadrži još 23 zahteva.
YUP-641/00A 1998-04-24 1999-04-20 Postupak za sintetizovanje inhibitora cox-2 RS49945B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8288898P 1998-04-24 1998-04-24
US8566898P 1998-05-15 1998-05-15

Publications (2)

Publication Number Publication Date
YU64100A YU64100A (sh) 2002-11-15
RS49945B true RS49945B (sr) 2008-09-29

Family

ID=26767964

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-641/00A RS49945B (sr) 1998-04-24 1999-04-20 Postupak za sintetizovanje inhibitora cox-2

Country Status (28)

Country Link
US (2) US6040319A (sr)
EP (1) EP1071745B1 (sr)
JP (2) JP3325264B2 (sr)
KR (1) KR100414998B1 (sr)
CN (1) CN1178658C (sr)
AR (1) AR015279A1 (sr)
AT (1) ATE272613T1 (sr)
AU (1) AU759469B2 (sr)
BR (2) BR9909844B1 (sr)
CA (1) CA2329193C (sr)
CZ (1) CZ292515B6 (sr)
DE (1) DE69919151T2 (sr)
DK (1) DK1071745T3 (sr)
EA (1) EA002975B1 (sr)
ES (1) ES2226378T3 (sr)
HK (1) HK1031399A1 (sr)
HR (1) HRP20000722B1 (sr)
HU (1) HU227627B1 (sr)
IL (2) IL139127A0 (sr)
NZ (1) NZ507597A (sr)
PL (1) PL193248B1 (sr)
PT (1) PT1071745E (sr)
RS (1) RS49945B (sr)
SI (1) SI1071745T1 (sr)
SK (1) SK284805B6 (sr)
TW (1) TW474934B (sr)
UA (1) UA57143C2 (sr)
WO (1) WO1999055830A2 (sr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861419A (en) 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
ATE253559T1 (de) * 1999-01-14 2003-11-15 Lonza Ag Verfahren zur herstellung von 1-(6-methylpyridin- 3-yl)-2- 4-(methylsulfonyl phenyl)ethanon
MXPA01007169A (es) 1999-01-14 2003-06-06 Lonza Ag 1-(6-metilpiridin-3-il)-2-(4-(metilsulfonil)fenil)etanona y metodo para su elaboracion.
JP2001115963A (ja) 1999-10-13 2001-04-27 Daikin Ind Ltd 圧縮機
US6858631B1 (en) 1999-11-29 2005-02-22 Merck & Co., Inc. Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl
DK1248618T3 (da) * 1999-11-29 2006-07-10 Merck Frosst Canada Inc Polymorfe, amorfe og hydratiserede former af 5-chlor-3-(4-methansulfonylphenyl)-6'-methyl-[2,3']bipyridinyl
JP2003523954A (ja) * 1999-12-08 2003-08-12 ファルマシア コーポレイション 治療効果が迅速に開始されるシクロオキシゲナーゼ−２阻害剤組成物
JP2001261653A (ja) * 2000-03-17 2001-09-26 Sankio Chemical Co Ltd ピリジン誘導体の合成法
US6521642B2 (en) 2000-05-26 2003-02-18 Merck & Co., Inc. 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis
US6800647B2 (en) 2000-05-26 2004-10-05 Merck & Co., Inc. 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3]bipyridinyl in pure crystalline form and process for synthesis
PH12001001175B1 (en) * 2000-05-26 2006-08-10 Merck Sharp & Dohme 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- (2,3')bipyridinyl in pure crystalline form and process for synthesis
CA2414674A1 (en) * 2000-07-13 2002-01-24 Pharmacia Corporation Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
PE20021017A1 (es) 2001-04-03 2002-11-24 Pharmacia Corp Composicion parenteral reconstituible
WO2002089798A2 (en) * 2001-05-04 2002-11-14 Merck & Co., Inc. Method and compositions for treating migraines
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
JP4700916B2 (ja) * 2004-02-02 2011-06-15 富士フイルムファインケミカルズ株式会社 ピリジン誘導体の製造方法
US7271383B2 (en) * 2004-08-11 2007-09-18 Lexmark International, Inc. Scanning system with feedback for a MEMS oscillating scanner
EP1784179A4 (en) 2004-08-24 2010-03-31 Merck Sharp & Dohme COMBINATION THERAPY FOR THE TREATMENT OF CYCLOOXYGENASE-2-MEDIATED DISEASES OR CONDITIONS IN PATIENTS WITH RISK TO THROMBOTIC CARDIOVASCULAR EVENTS
US20100111858A1 (en) * 2007-01-19 2010-05-06 Howard Carol P Diangostic and Therapeutic Cyclooxygenase-2 Binding Ligands
EP2479166B1 (en) 2009-02-27 2014-08-20 Cadila Healthcare Limited A process for the preparation of etoricoxib
EP2582690B1 (en) 2010-06-16 2018-07-25 Glenmark Generics Limited Process for preparation of 2, 3-diaryl-5-substituted pyridines and their intermediates
MY163379A (en) 2010-11-15 2017-09-15 Virdev Intermediates Pvt Ltd A process for cyclooxygenase-2 selective inhibitor
ITMI20110362A1 (it) 2011-03-09 2012-09-10 F I S Fabbrica Italiana Sint P A Procedimento per la preparazione di 1-(6-metilpiridin-3-il)-2-[4-(metilsolfonil)fenil]etanone, un intermedio dell'etoricoxib.
SI2714676T1 (sl) 2011-05-27 2019-06-28 Farma Grs, D.O.O. Postopek za pripravo polimorfne oblike I etorikoksiba
ITMI20111455A1 (it) 2011-07-29 2013-01-30 Italiana Sint Spa Nuovo procedimento per la preparazione di 1-(6-metilpiridin-3-il)-2-[4-(metilsolfonil)fenil]etanone, un intermedio dell'etoricoxib.
CN103204803A (zh) 2012-01-13 2013-07-17 阿尔弗雷德·E·蒂芬巴赫尔有限责任两合公司 用于合成依托考昔的方法
ITMI20120394A1 (it) * 2012-03-14 2013-09-15 Zach System Spa Processo di sintesi di un chetosolfone derivato
WO2013144977A2 (en) 2012-03-30 2013-10-03 Mylan Laboratories Ltd. An improved process for the preparation of etoricoxib
GR1007973B (el) * 2012-06-26 2013-09-12 Φαρματεν Αβεε, Νεα ν-οξοιμινο παραγωγα ως ενδιαμεσα μιας βελτιωμενης μεθοδου παρασκευης 2,3-διαρυλο-5-υποκατεστημενων πυριδινων
EP2887924B1 (en) 2012-08-27 2017-03-29 Cadila Healthcare Limited Pharmaceutical compositions of etoricoxib
ITVI20130014A1 (it) 2013-01-22 2014-07-23 Italiana Sint Spa Procedimento molto efficiente per preparare un intermedio di etoricoxib
WO2014114352A1 (en) * 2013-01-25 2014-07-31 Synthon Bv Process for making etoricoxib
CN104418799A (zh) * 2013-09-03 2015-03-18 天津药物研究院 一种依托考昔的晶型及其制备方法和应用
WO2015036550A1 (en) 2013-09-13 2015-03-19 Synthon B.V. Process for making etoricoxib
US10500178B2 (en) 2015-03-13 2019-12-10 The Board Of Trustees Of The Leland Stanford Junior University LTB4 inhibition to prevent and treat human lymphedema
CN104817473A (zh) * 2015-03-27 2015-08-05 南京大学 1-二甲氨基-3-二甲亚胺基-2-氯丙烯高氯酸盐在制备依托考昔中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA988522A (en) * 1972-05-05 1976-05-04 Haydn W.R. Williams 1,8-naphthyridine compounds
DE3842062A1 (de) * 1988-12-14 1990-06-28 Hoechst Ag Explosionssichere 1-dimethylamino-3-dimethylimino-2-arylpropen-1-salze, verfahren zu ihrer herstellung und ihre verwendung
HU227732B1 (en) * 1996-07-18 2012-01-30 Merck Frosst Canada Ltd Substituted pyridine derivatives as selective cyclooxigenase-2 inhibitors and use thereof
US5861419A (en) * 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors

Also Published As

Publication number Publication date
KR20010042941A (ko) 2001-05-25
CA2329193A1 (en) 1999-11-04
PL344108A1 (en) 2001-09-24
EP1071745A2 (en) 2001-01-31
CZ292515B6 (cs) 2003-10-15
US6252116B1 (en) 2001-06-26
ATE272613T1 (de) 2004-08-15
EA002975B1 (ru) 2002-12-26
HU227627B1 (en) 2011-10-28
PT1071745E (pt) 2004-11-30
DK1071745T3 (da) 2004-11-29
AU759469B2 (en) 2003-04-17
HRP20000722B1 (en) 2009-07-31
HRP20000722A2 (en) 2001-06-30
DE69919151T2 (de) 2005-07-28
YU64100A (sh) 2002-11-15
IL139127A (en) 2006-07-05
CA2329193C (en) 2007-01-23
BRPI9917739B1 (pt) 2016-05-03
JP3325264B2 (ja) 2002-09-17
JP2003040852A (ja) 2003-02-13
EP1071745B1 (en) 2004-08-04
EP1071745A4 (en) 2002-05-15
IL139127A0 (en) 2001-11-25
PL193248B1 (pl) 2007-01-31
JP2002513035A (ja) 2002-05-08
BR9909844B1 (pt) 2010-10-19
HUP0101407A3 (en) 2002-12-28
UA57143C2 (uk) 2003-06-16
HUP0101407A2 (hu) 2001-09-28
DE69919151D1 (de) 2004-09-09
SK284805B6 (sk) 2005-11-03
EA200001102A1 (ru) 2001-04-23
CN1306425A (zh) 2001-08-01
US6040319A (en) 2000-03-21
CN1178658C (zh) 2004-12-08
CZ20003940A3 (en) 2001-06-13
WO1999055830A2 (en) 1999-11-04
KR100414998B1 (ko) 2004-01-13
TW474934B (en) 2002-02-01
WO1999055830A3 (en) 1999-12-29
JP3834263B2 (ja) 2006-10-18
AR015279A1 (es) 2001-04-18
BRPI9917739B8 (pt) 2021-05-25
SK15892000A3 (sk) 2001-07-10
HK1031399A1 (en) 2001-06-15
AU3655799A (en) 1999-11-16
ES2226378T3 (es) 2005-03-16
BR9909844A (pt) 2001-04-03
NZ507597A (en) 2004-02-27
SI1071745T1 (en) 2004-10-31

Similar Documents

Publication Publication Date Title
RS49945B (sr) Postupak za sintetizovanje inhibitora cox-2
DE69726309D1 (de) Zuckerderivate, geliermittel, geliermittelzubereitungen, verfahren zu ihrer herstellung und gelzubereitungen
BR8704582A (pt) Processo para preparar derivados de piridinacarboxamida
MY131657A (en) Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
NL930018I1 (nl) (Piperidinylalkyl) chinazolinederivaten,werkwijze voor hun bereiding en farmaceutische preparaten die ze bevatten
FR2662440B1 (fr) Procede de preparation stereoselective de derives de la phenylisoserine.
AU6822798A (en) Cycloalkylalkanecarboxamides and the production and use thereof
PT87578A (pt) Process for the preparation of new alkanesulfonanilide derivatives and of pharmaceutical composition comprising the same
DE60235365D1 (de) Verfahren zur herstellung von 7-amino-syn-3,5-dihydroxyheptansäurederivaten und zwischenverbindungen diesesverfahrens und deren herestellung
GB1422720A (en) Production of aryl-4,4-bis dialkylamino- benzhydryl- sulphones
DK0873327T3 (da) Fremgangsmåde til fremstilling af 2-chlor-5-chlormethyl-thiazol
RS49829B (sr) Postupak i intermedijeri za proizvodnju piridin-2,3-dikarboksilat jedinjenja
PL341281A1 (en) Novel acronicin compounds, method of obtaining them and pharmacological compoistions containing such compounds
YU238990A (sh) Imidazo (4,5-c) piridini kao antiostereoporozna sredstva
AU3086689A (en) Substituted hydrazones and fungicides containing these compounds
AU587086B2 (en) New pyridine compounds with basic substituents, a process for their preparation, medicaments containing them, and their use
EP0169009A3 (en) Novel dihydropyridine derivatives and their production, formulation and use as pharmaceuticals
YU74501A (sh) Sinteza 3-amino-3-aril propionata
KR950029263A (ko) 3(2h)-푸란온 유도체
YU63196A (sh) Postupak za dobijanje dioksoazabicikloheksana
DK11783D0 (da) Fremgangsmade til fremstilling af 2-halogenpyridinderivater
NO993608D0 (no) Nye 8H-tieno-[2,3-b]pyrrolizin-8-on forbindelser, fremgangsmåte ved deres fremstilling og farmasoeytiske sammensetninger inneholdende dem
ATE263766T1 (de) Verfahren zur synthese von carbapenem- zwischenprodukten
PL89131B1 (en) Isoindolino-quinoline derivs - useful as tranquillizers and anticonvulsants[FR2167217A1]
JPS6422854A (en) Quinoline-3-carboxylic acid derivative